U.s. food & drug administration grants priority review of maribavir for the treatment of post-transplant recipients with cytomegalovirus infection in those resistant and/or refractory to prior anti-cmv treatment

Osaka, japan--(business wire)--takeda pharmaceutical company limited takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that the u.s. food & drug administration (fda) has accepted a new drug application (nda) for maribavir for the treatment of cmv infection in those that are refractory with or without resistance (r/r), in solid organ transplant (sot) or hematopoietic cell transplant (hct) recipients. this is an inflection year for takeda's pipeline with up
TAK Ratings Summary
TAK Quant Ranking